Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 May 1;22(5):473-474.
doi: 10.5588/ijtld.18.0210.

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis

Gustavo E Velásquez  1 , Geraint R Davies  2 , Carole D Mitnick  3
Affiliations
Editorial

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis

Gustavo E Velásquez et al. Int J Tuberc Lung Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none declared.

Comment on

References

    1. Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, et al. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis. 2018;22:537–543. - PMC - PubMed
    1. Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis. 1999;3(Suppl 3):S309–S316. - PubMed
    1. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein MB, et al. Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob Agents Chemother. 2017;61(8):e00038–17. - PMC - PubMed
    1. Boeree MJ, Diacon AH, Dawson R, Narunsky K, Bois du J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065. - PubMed
    1. Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, et al. Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61(11):e01054–17. - PMC - PubMed

LinkOut - more resources